Who are irinotecan + Carboplatin + erbitux's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Eloxatin, Platinum + Gemcitabine, chemotherapy plus p53, Methoxsalen+ECP, TAC chemotherapy, Oxaliplatin;Capecitabine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/irinotecan-carboplatin-erbitux.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

irinotecan + Carboplatin + erbitux — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

irinotecan + Carboplatin + erbitux (irinotecan-carboplatin-erbitux) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: chemotherapy. Area: Oncology.

marketed chemotherapy topoisomerase I, platinum DNA damage, epidermal growth factor receptor Oncology Live · refreshed every 30 min

Target snapshot

irinotecan + Carboplatin + erbitux (irinotecan-carboplatin-erbitux) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
irinotecan + Carboplatin + erbitux TARGET	irinotecan-carboplatin-erbitux	Pfizer	marketed	chemotherapy	topoisomerase I, platinum DNA damage, epidermal growth factor receptor
Eloxatin	Oxaliplatin	Yakult Honsha	marketed	Platinum-based chemotherapy agent	DNA	2002-01-01
Platinum + Gemcitabine	Platinum + Gemcitabine	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	marketed	Chemotherapy combination (platinum agent + nucleoside analog)	DNA (platinum crosslinking); ribonucleotide reductase and DNA polymerase (gemcitabine)
chemotherapy plus p53	chemotherapy plus p53	Shenzhen SiBiono GeneTech Co.,Ltd	marketed	Combination chemotherapy with p53 gene therapy	p53 tumor suppressor protein
Methoxsalen+ECP	Methoxsalen+ECP	M.D. Anderson Cancer Center	marketed	Photochemotherapy agent
TAC chemotherapy	TAC chemotherapy	Agendia	marketed	Chemotherapy regimen (combination)
Oxaliplatin;Capecitabine	Oxaliplatin;Capecitabine	Hebei Medical University	marketed	Platinum-based chemotherapy combination; antimetabolite	DNA (oxaliplatin); thymidylate synthase (capecitabine/5-FU)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (chemotherapy class)

Pfizer · 3 drugs in this class
Chengdu New Radiomedicine Technology Co. LTD. · 1 drug in this class
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · 1 drug in this class
Chinese Society of Lung Cancer · 1 drug in this class
Hutchmed · 1 drug in this class
Prof. Massimo Aglietta · 1 drug in this class
Sanofi · 1 drug in this class
Sun Yat-sen University · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Swiss Cancer Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). irinotecan + Carboplatin + erbitux — Competitive Intelligence Brief. https://druglandscape.com/ci/irinotecan-carboplatin-erbitux. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab